vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)
Milestone advances Phase 3 program toward topline results expected in mid 2027 Milestone advances Phase 3 program toward topline results expected in mid 2027